Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47, while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| VEA | VRTX | |
|---|---|---|
52-Week High | $72.39 | $529.59 |
52-Week Low | $56.02 | $366.54 |
Market Cap | — | $121.95B |
Sector | — | Health |
Enterprise Value | — | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
